Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02354170 · ClinicalTrials.gov registry record · Phase 2
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
A Phase 2 study of Central Serous Chorioretinopathy, sponsored by Roger Goldberg, M.D., MBA.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT02354170: Completed Phase 2 study of Central Serous Chorioretinopathy, sponsored by Roger Goldberg, M.D., MBA.
NCT02354170 is a Phase 2 study of Central Serous Chorioretinopathy that has completed, run by Roger Goldberg, M.D., MBA. The registered enrollment target is 16 participants, below the 86-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02354170, a Phase 2 study of Central Serous Chorioretinopathy, has completed, sponsored by Roger Goldberg, M.D., MBA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of the study is to assess the efficacy and safety of mifepristone 300 or 900-mg once-daily dosing by mouth for 4 weeks in patients with central serous chorioretinopathy.
Primary Outcome
Presence or absence of subretinal fluid on spectral-domain OCT after 4 weeks of treatment with mifepristone 300 or 900 mg daily, compared with placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mifepristone
Study Locations (2)
California
- Bay Area Retina Associates - Walnut Creek
Massachusetts
- Ophthalmic Consultants of Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-04-27 |
| Phase | Phase 2 |
What the finished NCT02354170 record still lists
NCT02354170 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 86-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02354170 reports a single indexed study location in California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02354170 about?
NCT02354170 is a clinical study titled "Short-Term Oral Mifepristone for Central Serous Chorioretinopathy". The goal of the study is to assess the efficacy and safety of mifepristone 300 or 900-mg once-daily dosing by mouth for 4 weeks in patients with central serous chorioretinopathy.
What is the current status of trial NCT02354170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-01. Estimated completion is 2017-04-27.
What conditions does trial NCT02354170 study?
This clinical trial studies the following conditions: Central Serous Chorioretinopathy.
What interventions are being tested in trial NCT02354170?
The interventions under investigation include: Placebo (DRUG), Mifepristone (DRUG).
Who is sponsoring clinical trial NCT02354170?
This trial is sponsored by Roger Goldberg, M.D., MBA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02354170 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Serous Chorioretinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
OCT in Rare Chorioretinal Diseases
RECRUITING
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
Eplerenone for the Treatment of Central Serous Chorioretinopathy
COMPLETED · NA
-
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia